Merus NV (NASDAQ:MRUS)

22.02
Delayed Data
As of Jun 24
 +0.68 / +3.19%
Today’s Change
13.47
Today|||52-Week Range
33.09
-30.75%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$959.0M

Company Description

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Contact Information

Merus NV
Yalelaan 62
Utrecht Utrecht 3584 CM
P:(130) 253-8800
Investor Relations:
316174014499

Employees

Shareholders

Other institutional41.99%
Mutual fund holders23.70%
Individual stakeholders22.29%

Top Executives

Bill LundbergPresident, CEO, CFO & Non-Executive Director
John de KruifChief Technology Officer & Senior Vice President
Ernesto WassermanSenior Vice President-Clinical Development
Andrew JoeChief Medical Officer
Cecilia Anna Wilhelmina GeuijenChief Scientific Officer & Senior Vice President